NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation develops advanced medical devices focused on minimally invasive diagnostics and therapeutics, utilizing unique thin-film electrode technology for effective neurosurgical applications. Founded in 2009 and headquartered in Eden Prairie, US, NeuroOne Medical Technologies specializes in creating innovative medical devices. The company has engaged in six deals to date, with the latest funding round raising USD 0. 15 mn.

The CEO, Dave Rosa, leads the team in their mission to enhance patient care through cutting-edge technology. NeuroOne specializes in the development of high-definition, minimally invasive diagnostic and therapeutic devices utilizing a unique thin-film electrode technology. Their flagship product, the OneRF™ Radiofrequency Ablation System, is designed for creating radiofrequency lesions in nervous tissue, specifically targeting functional neurosurgical procedures such as those for epilepsy. This system offers physicians enhanced capabilities for bedside monitoring, mapping, and ablation, ultimately aiming to improve therapeutic outcomes for patients suffering from drug-resistant epilepsy.

Additionally, NeuroOne's Evo® sEEG and Evo® Cortical Electrodes provide advanced solutions for temporary brain monitoring and mapping, enhancing surgical implant options while reducing infection risks. The company primarily serves healthcare providers, including hospitals and surgical centers, within the United States, as well as international markets in Europe and Asia. In the most recent fiscal year 2024, NeuroOne reported revenues of USD 3. 45 mn.

The company’s revenue model revolves around the direct sale of its specialized medical devices to healthcare institutions, focusing on long-term partnerships with hospitals and surgical centers. Their products are tailored to the healthcare market, reflecting advanced technology and unique capabilities, and include standalone systems or broader surgical solutions with accessories and support services. NeuroOne Medical Technologies plans to leverage recent funding to advance the development of upcoming products, including enhancements to their existing technologies and potential new offerings. They are targeting expansion into international markets, particularly in Europe and Asia, within the next two years.

This strategy aligns with their commitment to enhancing their product portfolio and reaching more healthcare providers globally.